Pharmacotherapy of schizophrenia patients with comorbid substance abuse

Schizophrenia Bulletin
J N Wilkins

Abstract

Substance abuse worsens the course of schizophrenia and significantly impairs the relationship between the patient and the health care team. Recent advances in laboratory studies of substance abuse and the pharmacology of schizophrenia open up new possibilities for pharmacotherapy of substance abuse in schizophrenia patients. D1 dopaminergic receptor agonists may directly block the drive for stimulant use. D2 dopaminergic receptor antagonists may indirectly block the drive for stimulant and nicotine use, while opioid antagonists appear to reduce the drive to use alcohol. New generations of neuroleptics with serotonin (5-HT2) receptor antagonism and/or 5-HT1A agonist activity may reduce substance abuse in schizophrenia patients who self-medicate negative symptoms or neuroleptic side effects. Pharmacotherapy efficacy may be enhanced by adding contingency management, social skills training, and other manualized programs. Tables are provided of potentially useful medications. Preliminary results are presented of cocaine-abusing schizophrenia patient treated with desipramine and traditional neuroleptics.

Citations

Jul 31, 1999·Drug and Alcohol Dependence·H Zeitlin
Jul 6, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·P Batel
Sep 7, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M Soyka, J De Vry
Apr 19, 2003·International Clinical Psychopharmacology·Stéphane PotvinJean-Yves Roy
Dec 5, 2015·Expert Opinion on Pharmacotherapy·Jean-Michel AzorinRaoul Belzeaux
Feb 15, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaUNKNOWN WFSBP Task Force on Treatment Guidelines for Substance Use Disorders
Apr 9, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·T Wobrock, M Soyka
Jun 11, 2002·Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie·C FleischhakerH Remschmidt
Nov 24, 2004·Biological Psychiatry·Thomas R Kosten, Therese A Kosten
Apr 10, 2003·The Psychiatric Clinics of North America·Alan I GreenJoanne D Wojcik
Oct 30, 2015·Journal of Psychopharmacology·Robin P Wilson, Sagnik Bhattacharyya
Jul 14, 2005·Journal of Clinical Psychopharmacology·Thomas P BeresfordHenry F Beresford
Nov 18, 2006·Expert Opinion on Pharmacotherapy·Michael Soyka, Susanne Roesner
Jan 4, 2003·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Helen DermatisLaurence Westreich
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Mar 16, 2007·Acta Psychiatrica Scandinavica·J Addington, D Addington
Jun 30, 2005·Journal of Psychiatric Practice·Evaristo O Akerele, Frances R Levin
May 28, 2005·The Journal of Nervous and Mental Disease·Steven L SayersStanley N Caroff
Feb 2, 2006·The American Journal on Addictions·Ismene L PetrakisRobert Rosenheck
Sep 14, 2007·European Addiction Research·Luis SanJose Martinez-Raga
Feb 5, 2009·Expert Opinion on Pharmacotherapy·Thomas Wobrock, Michael Soyka
Mar 31, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Aug 16, 2003·Journal of Clinical Psychopharmacology·S Pirzada SattarFrederick Petty
Oct 8, 1998·The Annals of Pharmacotherapy·P F Buckley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alcohol Use Disorder

Alcohol use disorder involves a pattern of alcohol consumption that includes compulsive use and a loss of control over intake of alcohol. The impact on physical health, socioeconomic factors, and psychiatric health is profound. Find the latest research on alcohol use disorder here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here